Wuhan Moore Biotechnology Co., Ltd.

Wuhan Moore Biotechnology Co., Ltd. was established in 2008 with a registered capital of 21.4824 million yuan. It is a high-tech enterprise specializing in the research and development of peptide biological new drugs. It is a national "double" project construction unit and a high-tech enterprise in Hubei Province. It has built the "Moore Biology — Wuhan University Active Substance Research and Development Center" and academician expert workstation. It has obtained more than 20 national invention patents and has undertaken 2 major national major new drug creation science and technology projects. The company has established a full-chain peptide drug research and development platform (peptide gene engineering expression/purification, molecular screening design and target research, biologic drug identification and analysis, new preparations, etc.), equipped with 180 sets of high-end equipment. By the end of 2025, it will put into production a 14,500 ㎡ digital GMP genetic engineering production platform and cell production platform that meets the requirements of GMP in China, the United States, and Europe. It can produce 200kg of simaglutide API and other genetically engineered peptide products annually, and is being inspected by the Hubei Provincial Pharmaceutical Administration for drug production licenses. Products include Simiglutide APIs and backbone, liraglutide, HPV-BVTAG protein, HBV-PreS1 protein, and engineering enzymes; provide CDMO customization services (mg to kg) such as molecular screening, design, expression, purification, identification, process development, and quality control of polypeptide drugs.

Wuhan Moore Biotechnology Co., Ltd. is located at No. 278, Donghuxinjishu Development Zone Gaoxinwu Road Qianyanshengwuchanyejididong, Wuhan, China.

Finished peptide dosage forms available.

Website: https://www.more-bio.com.cn